0.02Open0.05Pre Close9 Volume345 Open Interest7.00Strike Price24.00Turnover79.21%IV10.18%PremiumDec 27, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.0967Delta0.2684Gamma258.67Leverage Ratio-0.0131Theta-0.0001Rho-25.00Eff Leverage0.0014Vega
Altimmune Stock Discussion
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
No comment yet